TB-500 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: TB-500 evidence and protocol review

Structural Research peptide LyophilizedCapsule verified

Also known as: TB500, Ac-LKKTETQ, Thymosin beta-4 fragment

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

5 mg, 10 mg, 20 mg

Calculator

Preset available

Storage

Lyophilized: store at -20 deg C, protected from light. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA.

Solubility

Form, salt, and formulation dependent; verify the lot-specific COA

Catalog Description

TB-500 refers to research material related to thymosin beta-4 (Tbeta4), a naturally occurring actin-sequestering peptide. In a rat full-thickness wound model (Malinda et al.), topical or intraperitoneal Tbeta4 increased reepithelialization by 42% over controls at 4 days and up to 61% at 7 days, with greater wound contraction, increased collagen deposition, and angiogenesis versus controls. Mechanistically, Tbeta4 binds and sequesters G-actin, promoting migration of endothelial cells, keratinocytes, and progenitor cells to injury sites; the LKKTET sequence within the peptide contributes to its angiogenic activity via VEGF pathway involvement. Evidence base is predominantly preclinical (rodent, cell culture).

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

In horses after 10 mg SC, plasma peaked at 60-120 minutes and became unquantifiable at 6-10 hours; this is not a human half-life

Onset

Rodent models show measurable wound-healing effects within 4-7 days

Administration Routes (Research)

Topical in non-acetylated mouse-fragment researchSC in horsesIP in ratsNo validated human route

Reported Research Effects

Accelerated reepithelialization in rodent wound models
Increased wound contraction and collagen deposition
Promotes endothelial/keratinocyte/progenitor cell migration
Angiogenesis via actin-regulation and VEGF pathway involvement

Reported Research Side Effects

No human safety profile
Commercial naming may refer to different salts, derivatives, or active moieties
Non-acetylated LKKTETQ animal data cannot be directly extrapolated to N-acetylated TB-500
FDA found no acute or repeat-dose toxicology adequate for human compounding evaluation

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

No human administration protocol for exact N-acetylated TB-500 was identified by FDA [Research only; Human protocol absent; Not established]Source: FDA 503A bulk-substance review
0.01% non-acetylated LKKTETQ in 50 mcL PBS applied to each mouse wound on day 0 and again 48 hours later [Topical; Aged-mouse wound model; Two applications]Source: FDA summary of Philp et al. 2003; not exact acetylated TB-500
10 mg SC once in thoroughbred geldings for pharmacokinetic characterization [SC; Equine research; Single dose]Source: FDA summary of Ho et al. 2012
50 mg/kg IP once in rats for metabolite characterization [IP; Rat research; Single dose]Source: FDA summary of Rahaman et al. 2024

Research Notes

FDA identifies TB-500 as Ac-LKKTETQ, the acetylated 17-23 fragment of full-length thymosin beta-4, and explicitly states that they are not the same substance. No human administration study was found. This row therefore lists the actual animal and in-vitro test protocols while blocking transfer of full-length Tbeta4 clinical claims.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

FDA Pharmacy Compounding Advisory Committee briefing: TB-500 — U.S. Food and Drug Administration
https://www.fda.gov/media/193349/download

Doping-control structural identification of TB-500 — Ghent University repository
https://backoffice.biblio.ugent.be/download/5924383/5924459

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.